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BACKGROUND: The liver is the primary source of circulating insulin-like growth factor (IGF)-I, yet the relation between IGFs and liver
cancer is uncertain.
METHODS: In a case–cohort study within a cohort of 29133 male smokers we examined associations of serum IGF-I and IGF binding
protein (IGFBP)-3 with liver cancer (50 cases).
RESULTS: Nonlinear associations between liver cancer and IGF-I and IGFBP-3 were observed (P¼0.04 and Po0.01, respectively),
strongest association at lowest levels (odds ratio (OR)¼0.2, 95% confidence interval (CI)¼0.1–0.7 for 80 vs 30ngml
 1 of IGF-I;
OR¼0.2, 95% CI¼0.1–0.6 for 1400 vs 700ngml
 1 of IGFBP-3).
CONCLUSIONS: Low IGF-I and IGFBP-3 levels in male smokers are associated with increased risk of liver cancer.
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Liver cancer is the fifth most common cancer worldwide
(Bosch et al, 2004), occurs more commonly in men, and has a
high fatality among affected patients. Although populations of
developing countries have the highest risk with the primary cause
being hepatitis B virus (HBV) infection, a trend of increasing
incidence has been observed in developed countries (McGlynn
et al, 2001). Hepatocellular carcinoma (HCC) accounts for over
85% of cases, but underlying mechanisms of hepatocarcinogenesis
are not completely understood and may vary across risk factors
(Scharf and Braulke, 2003).
The liver is the primary source of circulating insulin-like growth
factor(IGF)-I, a peptide hormone of which levels peak at puberty
and decrease thereafter (Juul, 2003; Pavelic et al, 2007). IGF-I has
been implicated in the regulation of cancer cells through effects on
proliferation, differentiation, and apoptosis (Dunn et al, 1997;
Pollak, 2000; Moschos and Mantzoros, 2002; Sachdev and Yee,
2007). Pituitary secretion of growth hormone stimulates hepatic
IGF-I production, and more than 75% of circulating IGF-I is bound
and regulated by IGF binding protein (IGFBP)-3 (Ferry et al, 1999).
Although previous studies showed an association between high
serum concentrations of IGF-I and risk of prostate, colorectal,
and breast cancers (Rowlands et al, 2009; Chan et al, 1998, 2002;
Ma et al, 1999; Yu et al, 2002; Renehan et al, 2004), subsequent
studies have found low IGF-I levels to be associated with an
increased risk for brain and kidney cancer (Lonn et al, 2007; Major
et al, 2010). Clinical studies suggest a possible inverse IGF-liver
function association, although reverse causality, with low IGF-I
levels being a consequence of liver damage, remains a possibility
(Wu et al, 1988; Buzzelli et al, 1993). Several studies reported
the reduced IGF levels to be independent of liver function and
progression of disease, providing support for a potential causal
connection (Stuver et al, 2000; Mazziotti et al, 2002; Mattera et al,
2003; Elsammak et al, 2006). However, these studies involved
patients who already had cirrhosis or hepatitis C virus (HCV)-
related liver disease.
Unlike above investigations, the a-Tocopherol, b-Carotene
Cancer Prevention (ATBC) Study has a prospective design and
involved a large population of men who, although being smokers,
did not have liver cirrhosis, chronic alcohol abuse, or cancer at
enrolment. In addition, the ATBC Study was conducted in Finland,
a developed country with an extremely low prevalence of viral
infections of the liver (e.g., HBV, HCV). We conducted
a case–cohort study to assess the independent roles of IGF-I
and IGFBP-3 in liver cancer aetiology in a population without
preexisting diseases that are known risk factors.
MATERIALS AND METHODS
The ATBC Study was a randomised, placebo-controlled trial
that evaluated the effect of supplementation with a-tocopherol,
b-carotene or both on the incidence of cancer (The ATBC Cancer
Prevention Study Group, 1994). In 1985–88, 29133 eligible men
in southwestern Finland, aged 50–69 years, who smoked at least
five cigarettes daily, were randomised to an intervention group.
Exclusion criteria included previous diagnosis of cancer (excluding
non-melanoma skin cancer), liver cirrhosis, chronic alcoholism, or
other medical conditions that might limit long-term participation.
All study participants gave written informed consent before
participation; the study was approved by the Institutional Review
Boards of the National Public Health Institute in Finland and the
US National Cancer Institute.
At study entry, participants completed an investigator-adminis-
tered baseline questionnaire that included data on demographics,
smoking habits, and medical history. Trained study staff measured
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yheight and weight at baseline using standard methods. Diet,
including alcohol intake, was assessed with a validated self-
administered food frequency questionnaire. Fasting serum
samples were collected from participants at their baseline visit
and stored at  701C until analyzed. IGF assays were performed in
the laboratory of Dr Pollak (McGill University, Montreal, QC,
Canada). Total serum IGF-I and IGFBP-3 were measured by
enzyme-linked immunosorbent assays after separation of IGFs
from IGFBPs by acid-ethanol extraction (Diagnostic Systems
Laboratory, Inc., Houston, TX, USA). The inter-batch assay
coefficient of variation (CV) was 4.6 and 6.2% for IGF-I and
IGFBP-3, respectively; the intra-batch assay CV was 5.2 and 4.2%,
respectively.
All participants in the current study were alive and without
evidence of cancer during the first 5 years of follow-up. Incident
cases of liver cancer were defined based on the International
Classification of Diseases 9; codes 155.0, 155.1, and 155.2. Cases
were identified through the Finnish Cancer Registry, which
provides almost 100% case ascertainment (Korhonen et al,
2002). Medical records for cases with a major cancer site were
reviewed centrally by two study physicians to confirm diagnoses
(The ATBC Cancer Prevention Study Group, 1994). Cancers
metastasised from other organ sites are not included in our
complement of cases. A subcohort group of 400 men was randomly
selected from the full ATBC Study population, representing
the comparison group. Follow-up for the current study included
time from randomisation through 31 December 1997, date of
diagnosis, or date of death (whichever occurred first).
Statistical analysis
Exposures of interest included baseline serum IGF-I, IGFBP-3,
and the IGF-I/IGFBP-3 molar ratio. Potential confounders included
age, anthropometric measures, lifestyle factors, and medical
history. IGF-I/IGFBP-3 molar ratio was calculated as a measure
of bioavailability using the following conversion: 1ngml
 1 IGF-I
¼0.130nmoll
 1 and 1ngml
 1 IGFBP-3 ¼0.036nmoll
 1. Body
mass index was calculated as weight in kilograms divided by
squared height in metres (kgm
 2).
General linear models adjusted for age were used to estimate least
square means and standard errors to help identify potential
confounders. Group comparisons for continuous variables were
performed using analysis of covariance; categorical variables were
compared using logistic regression. In addition, correlations between
IGF-I, IGFBP-3, and covariates adjusting for age were calculated
using Pearson’s partial correlations in the comparison group.
Given the small number of cases (n¼50), IGF measures were
analyzed as continuous predictors of liver cancer to maximise study
power to identify associations. Logistic regression models were used
to determine the appropriate functional form (e.g., linear or
quadratic; Woodward, 2005). Accordingly, models for IGF-I and
IGFBP-3 included a linear and a quadratic term to account for the
curvilinear relation with liver cancer risk (Hosmer and Lemeshow,
2000; Jewell, 2004). IGF-I/IGFBP-3 molar ratio was modelled as a
continuous linear variable. Odds ratios (ORs) and corresponding
95% confidence intervals were estimated for age- and multivariable-
adjusted models. Consistent with the interpretation of a continuous
variable, we report the ORs for 1-unit increments (e.g., 1-s.d.). As
for nonlinear associations the estimated risks will vary across the
IGF-axis, a single ‘overall’ OR cannot be calculated across the whole
range of IGF concentrations; therefore, we report the ORs for four
consecutive 1-s.d. increments.
All models included a continuous variable for age. Other
variables were included in the final model if they were associated
with both the exposure of interest and disease, changed the OR
by at least 10%, or had a P-value p0.20 in the full model. The
multivariable analyses did not include more covariates than
appropriate for the given number of cases (Peduzzi et al, 1996).
Possible effect modifications by body weight, cigarettes smoked,
and alcohol intake were examined by evaluating interaction terms
in the models; no significant interactions were observed.
RESULTS
Among the 50 incident liver cancer cases, 88% were adeno-
carcinomas. Age-adjusted characteristics at baseline are shown
in Table 1. On average, cases were older (mean age at
Table 1 Age and age-adjusted baseline characteristics of men, ATBC Study
Characteristic Cases (n¼50) Comparison group (n¼400) P-value
Age at randomisation (years) 60 (0.7) 56 (0.2) o0.01
Height (cm) 174.0 (0.9) 173.7 (0.3) 0.79
Weight (kg) 82.1 (1.9) 80.3 (0.7) 0.38
BMI (kgm
 2) 27.0 (0.6) 26.6 (0.2) 0.45
Serum total cholesterol (mmoll
 1) 6.0 (0.2) 6.3 (0.1) 0.04
Alcohol intake (g per day) 22.3 (3.6) 19.2 (1.2) 0.43
Smoking history
No. of cigarettes per day 23.7 (1.2) 20.3 (0.4) o0.01
No. of years smoked 36.8 (1.0) 35.3 (0.3) 0.16
Physical activity – leisure, n (%) 0.01
Light 31 (65.4) 172 (42.6) o0.01
Moderate 18 (33.4) 204 (51.3) 0.02
Heavy 1 (1.2) 24 (6.1) 0.16
Medical history
Diabetes, n (%) 5 (9.4) 18 (4.6) 0.16
Gallstones, n (%) 2 (2.9) 21 (5.4) 0.47
Insulin-like growth factor-I (ngml
 1) 115.2 (7.3) 146.3 (2.5) o0.01
Insulin-like growth factor BP-3 (ngml
 1) 2017.8 (92.5) 2387.9 (31.9) o0.01
IGF-I/IGFBP-3molar ratio 0.21 (0.01) 0.22 (0.003) 0.07
Abbreviations: ATBC¼a-Tocopherol, b-Carotene Cancer Prevention; BMI¼body mass index; IGF-I¼insulin-like growth factor-I; IGFBP-3¼IGF binding protein-3 Means (s.e.)
are reported unless otherwise indicated. P-values from generalised linear models.
IGF-I and liver cancer in male smokers
JM Major et al
1090












yrandomisation¼60 years), smoked more cigarettes daily, were less
physically active during leisure time, and had lower serum
cholesterol. Mean serum levels of IGF-I and IGFBP-3 were
significantly lower in cases than in the comparison group, after
adjusting for age: 115 vs 146ngml
 1 and 2018 vs 2388ngml
 1,
respectively (Po0.01). Intervention group assignment was not
associated with liver cancer (P¼0.28; data not shown).
Table 2 shows age and age-adjusted correlations of baseline
participant characteristics with IGF-I and IGFBP-3. As shown,
inversely correlated with serum IGF-I were age (P¼0.03), alcohol
intake (P¼0.04), and having diabetes (P¼0.03), whereas body
weight and IGFBP-3 were positively associated with IGF-I levels
(Po0.01), with IGFBP-3 and IGF-I having a moderately high
correlation of r¼0.69.
Age-adjusted logistic regression analyses show a significant
nonlinear association between liver cancer risk and serum IGF-I
and IGFBP-3 (Po0.05 and Po0.01, respectively; Table 3),
suggesting some curvature to the relationship between risk and
IGF levels such that the ORs vary across the range of IGF values.
Hence, ORs and 95% confidence intervals (CIs) are reported for
consecutive 1-s.d. intervals of 50ngml
 1 for IGF-I (700ngml
 1 for
IGFBP-3). In the present study, risk of liver cancer was 78%
lower for men with levels of 79ngml
 1 compared with 30ngml
 1,
66% lower for 129ngml
 1 compared with 80ngml
 1, and 47%
lower at 179ngml
 1 compared with 130ngml
 1, after adjustment
for age. The ratio of cases to comparison group in the lowest range
was 11:31 (35%). These results suggest that men with low levels of
IGF had greater risk. Study findings were not markedly different
after further adjusting for cigarettes smoked and physical activity.
IGFBP-3 levels did not alter the association between serum IGF-I
and risk of developing liver cancer. Similarly, risk was statistically
significant for the lowest IGFBP-3 levels; IGF-I levels did not alter
the risk-IGFBP-3 association (Table 3).
Although there was no evidence of a nonlinear relation (P¼0.38
for quadratic term) between the IGF-I/IGFBP-3 molar ratio and
risk, there was a suggested linear association such that for every
0.05-unit decrease in molar ratio, the odds of developing liver
cancer increased by a factor of 1.35 (¼1.0/0.74), after adjustment
for age, daily cigarettes, and physical activity (OR¼0.74; 95%
CI¼0.53–1.01), but this was not significant (P¼0.06).
DISCUSSION
This is the first population-based study to prospectively examine
the association of circulating IGF-I and IGFBP-3 levels with
development of liver cancer, doing so within a cohort of older
middle-aged men who, although smokers, did not have a history of
alcoholism, liver cirrhosis, or previous cancer, and who resided in
a country that has low prevalence of HBV and HCV infections. We
observed significant nonlinear associations between IGF-I and
IGFBP-3 and liver cancer risk, with the strongest association seen
in the lowest IGF range. These associations were not altered
markedly after adjusting for potential confounders. Interpretation
of results should be made with caution, however, given the small
number of cases.
Strengths of this investigation include the prospective study
design of the ATBC Study, in which IGF-I and IGFBP-3 were
measured from blood samples collected at the baseline visit,
preceding the development of liver cancer. The possibility that
IGF levels were influenced by subclinical liver cancer was
minimised by selecting participants who were alive and without
clinical evidence of cancer during the first 5 years of cohort
follow-up. A limitation of this study was the inability to directly
adjust for aflatoxin, HBV, and HCV, established risk factors for
liver cancer (London and McGlynn, 2006), even though the
prevalence of HBV and HCV infections in Finland is low; that is,
o0.001 and 0.4%, respectively (Iivonen et al, 2005; Shepard et al,
2005, 2006).
Our findings are consistent with those from the only other study
of liver cancer and IGF-1, in which patients with HCC were found
to have significantly lower IGF-I levels than age- and gender-
matched controls after adjusting for prothrombin time and serum
albumin levels, indicators of the degree of liver damage (Stuver
et al, 2000). Given the complexity of the IGF system and the
paucity of population-based studies examining the IGF-liver
cancer association, the pathophysiological mechanisms potentially
involved will remain for subsequent investigation to elucidate.
In conclusion, findings from this study suggest that IGF-I and
IGFBP-3 may have independent roles in development of liver
cancer. Confirmation of our results in other large, prospective
population-based studies is needed, including examination of
associations in women and nonsmokers.
Table 2 Age and age-adjusted partial correlations
IGF-I IGFBP-3
Characteristic rP - value rP - value
Age (years)  0.11 0.03  0.21 o0.01
Height (cm) 0.19 o0.01 0.17 o0.01
Weight (kg) 0.17 o0.01 0.25 o0.01
BMI (kgm
 2) 0.10 0.05 0.19 o0.01
Serum total cholesterol (mmoll
 1) 0.07 0.16 0.21 o0.01
Alcohol (g per day)  0.10 0.04  0.06 0.22
No. of cigarettes per day  0.06 0.22  0.05 0.32
No. of years smoked  0.04 0.48  0.09 0.08
Leisure physical activity (moderate+light) 0.09 0.06 0.12 0.02
Diabetes (yes/no)
a  0.11 0.03  0.05 0.36
History of gallstones (yes/no)  0.01 0.85 0.07 0.17
IGFBP-3 (ngml
 1) 0.69 o0.01 — —
Abbreviations: BMI¼body mass index; IGF-I¼insulin-like growth factor-I;
IGFBP-3¼IGF binding protein-3. r indicates Pearson’s partial correlations among
noncases (n¼400).
aDiabetes¼history of diabetes and/or fasting glucose
X126mgdl
 1.
Table 3 Associations between serum IGF measures and development
of liver cancer
Model 1 Model 2
Characteristic Cases OR 95% CI P-value OR 95% CI P-value
IGF-I (per 50ngm
 1l) 0.025 0.036
30–79 11 0.22 0.10–0.48 0.24 0.09–0.67
80–129 24 0.34 0.21–0.54 0.38 0.19–0.75
130–179 11 0.53 0.38–0.74 0.59 0.36–0.98
180+ 4 0.83 0.48–1.44 0.92 0.49–1.72
IGFBP-3 (per 700ngml
 1) 0.002 0.004
700–1399 14 0.14 0.06–0.35 0.23 0.08–0.64
1400–2099 21 0.30 0.18–0.49 0.45 0.23–0.88
2100–2799 9 0.63 0.45–0.87 0.91 0.55–1.49
2800+ 6 1.30 0.69–2.46 1.82 0.90–3.66
IGF-I/IGFBP-3molar ratio (per 0.05 units)
50 0.74 0.54–1.01 0.057 0.73 0.53–1.01 0.060
Abbreviations: CI¼confidence interval; IGF-I¼insulin-like growth factor-I;
IGFBP-3¼IGF binding protein-3; OR¼odds ratio. The association of IGF was
modelled as a continuous (rather than categorical) predictor of liver cancer. IGF-I and
IGFBP-3 were centred to prevent collinearity with the quadratic term. 1-s.d. increase
in IGF-I¼50ngml
 1; 1-s.d. increase in IGFBP-3¼700ngml
 1; P-value based on the
Wald test for quadratic term (IGF-I; IGFBP-3) and linear term (molar ratio). Model 1:
age-adjusted. Model 2: adjusted for age, cigarettes per day, leisure physical activity,
and IGFBP-3; adjusted for age, cigarettes per day, leisure physical activity, and
IGF-I; adjusted for age, cigarettes per day, and leisure physical activity.
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